In-depth exploration of the focus issues of TKI combined with radiotherapy for EGFR-mutant lung adenocarcinoma patients with brain metastasis: a systematic analysis based on literature metrology, meta-analysis, and real-world observational data.

Results demonstrated that iPFS2 (24.0 months, 95% CI: 19.270–28.730) and OS (38.0 months, 95% CI: 30.074–45.926) for the combination of third-generation TKIs and brain radiotherapy were significantly superior to those for brain radiotherapy alone (iPFS2: 8.0 months, 95% CI: 6.695–9.305; OS: 20.0 months, 95% CI: 24.108–23.116), with a highly significant difference ( P < 0.001; Table 5 , Fig. 6 G-H).

also in 132,142 other papers

Results The bibliometric analysis revealed an increasing trend in research focused on the combination of RT and TKIs for the management of lung cancer brain metastases over the previous decade.

also in 63,971 other papers